Vericel to Report Third-Quarter 2019 Financial Results on November 5, 2019
October 22 2019 - 7:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced the following webcast and conference call to discuss its
third-quarter 2019 financial results and business highlights.
What: |
|
Vericel Corporation Third-Quarter 2019 Earnings Call |
When: |
|
Tuesday, November 5, 2019 at 8:30am (EDT) |
Where: |
|
http://investors.vcel.com/events-presentations |
How: |
|
The conference call will be available live in the Investors
section of the Vericel website at
http://investors.vcel.com/events-presentations. Please access
the site at least 15 minutes prior to the scheduled start time in
order to download the required audio software if necessary.
Presentation slides for the conference call will be available on
the webcast and in the Investor Relations section of the Vericel
website. |
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation third-quarter 2019
earnings call. If calling from outside the U.S., please use
the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until November 5, 2020. A replay of the call will also be
available until 11:00am (EDT) on November 10, 2019 by calling (855)
859-2056, or from outside the U.S. (404) 537-3406. The
conference ID is 1685887.
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports
medicine and severe burn care markets. The company markets
two cell therapy products in the United States. MACI®
(autologous cultured chondrocytes on porcine collagen membrane) is
an autologous cellularized scaffold product indicated for the
repair of symptomatic, single or multiple full-thickness cartilage
defects of the knee with or without bone involvement in
adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American commercial rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the
company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound
Ltd. and is used under license to Vericel Corporation. © 2019
Vericel Corporation. All rights reserved.
Global Media Contacts: David SchullRusso
Partners LLCDavid.schull@russopartnersllc.com+1 212-845-4271
(office)+1 858-717-2310 (mobile)
Investor Contacts:Lee SternSolebury
Troutlstern@troutgroup.com+1 646-378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024